Serum lipoprotein(a) levels are greater in female than male patients with type-2 diabetes

Lipids

Volumn 46, Issue 4, 2011, Pages 349-356

  Nakhjavani, Manouchehr ^a   Morteza, Afsaneh ^a   Esteghamati, Alireza ^a   Khalilzadeh, Omid ^a   Zandieh, Ali ^a   Safari, Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dyslipidemia; Lipoprotein(a); Menopause; Type 2 diabetes; Women

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PREMENOPAUSE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ADULT; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MENOPAUSE; MIDDLE AGED; PREMENOPAUSE; RISK FACTORS; SEX FACTORS;

EID: 79956051476     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-010-3513-1     Document Type: Article

References (48)

1. Gu K, Cowie CC, Harris MI (1999) Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291-1297 (Pubitemid 29174480)
2. Kragelund C, Kober L, Faber J, Steffensen R, Hildebrandt P (2007) Metabolic syndrome and mortality in stable coronary heart disease: relation to gender. Int J Cardiol 121:62-67 (Pubitemid 47285381)
3. Szmuilowicz ED, Stuenkel CA, Seely EW (2009) Influence of menopause on diabetes and diabetes risk. Nat Rev Endocrinol 5:553-558
4. Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 5:150-159
5. Djindjic B, Rankovic G, Zivic M, Savic T, Spasic M, Bubanj M (2009) Gender difference in hypolipemic and anti-inflammatory effects of statins in diabetics with coronary artery disease. Vojnosanit Pregl 66:966-972
6. Njelekela MA, Mpembeni R, Muhihi A, Mligiliche NL, Spiegelman D, Hertzmark E, Liu E, Finkelstein JL, Fawzi WW, Willett WC, Mtabaji J (2009) Gender-related differences in the prevalence of cardiovascular disease risk factors and their correlates in urban Tanzania. BMC Cardiovasc Disord 9:30
7. Legato MJ, Gelzer A, Goland R, Ebner SA, Rajan S, Villagra V, Kosowski M (2006) Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 3:131-158 (Pubitemid 44069479)
8. Ariyo AA, Thach C, Tracy R (2003) Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 349:2108-2115 (Pubitemid 37464535)
9. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361:2518-2528
10. Tian H, Han L, Ren Y, Li X, Liang J (2003) Lipoprotein(a) level and lipids in type 2 diabetic patients and their normoglycemic first-degree relatives in type 2 diabetic pedigrees. Diabetes Res Clin Pract 59:63-69 (Pubitemid 35461911)
11. Murase T, Okubo M, Amemiya-Kudo M, Hiraga T, Oka J, Shimada M, Igarashi T (2007) Impact of markedly elevated serum lipoprotein(a) levels (> or = 100 mg/dL) on the risk of coronary heart disease. Metabolism 56:1187-1191 (Pubitemid 47223258)
12. Chien KL, Hsu HC, Su TC, Sung FC, Chen MF, Lee YT (2008) Lipoprotein(a) and cardiovascular disease in ethnic Chinese: the Chin-Shan Community Cardiovascular Cohort Study. Clin Chem 54:285-291
13. Murase T, Okubo M, Amemiya-Kudo M, Ebara T, Mori Y (2008) Impact of elevated serum lipoprotein(a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus. Metabolism 57:791-795 (Pubitemid 351697910)
14. Nasri H (2008) Association of serum lipoprotein(a) with hypertension in diabetic patients. Saudi J Kidney Dis Transpl 19:420-427
15. Wassef N, Sidhom G, Zakareya el K, Mohamed el K (1997) Lipoprotein(a) in android obesity and NIDDM. Diabetes Care 20:1693-1696
16. Khan MA, Baseer A (1998) Magnitude of lipoprotein(a) in diabetes mellitus. J Pak Med Assoc 48:11-13
17. Alsaeid M, Qabazard M, Shaltout A, Sharma PN (2001) Impact of glycemic control on serum lipoprotein(a) in Arab children with type 1 diabetes. Pediatr Int 43:246- 250
18. Habib SS, Aslam M (2003) High risk levels of lipoprotein(a) in Pakistani patients with type 2 diabetes mellitus. Saudi Med J 24:647-651 (Pubitemid 36833559)
19. Funatsu H, Shimizu E, Noma H, Mimura T, Hori S (2009) Association between serum lipoprotein(a) level and progression of non-proliferative diabetic retinopathy in type 2 diabetes. Acta Ophthalmol 87:501-505
20. Chen XF, Tang LJ, Jiang JJ, Jiang J, Hu XY, Yu WF, Wang JA (2008) Increased levels of lipoprotein(a) in non-smoking aortic dissection patients. Clin Exp Med 8:123-127 (Pubitemid 351999732)
21. Drobny M, Svalekova A, Koskova E, Hazlingerova M, Celec S (1996) Selected parameters of lipoprotein metabolism in cerebrovascular diseases. Bratisl Lek Listy 97:267-272
22. Fukunaga N, Anan F, Kaneda K, Nawata T, Saikawa T, Yoshimatsu H (2008) Lipoprotein(a) as a risk factor for silent cerebral infarction in hemodialysis patients. Metabolism 57:1323-1327
23. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, Rumley A, Lowe GD, Danesh J, Gudnason V (2008) Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 168:598-608 (Pubitemid 351468395)
24. Okosun IS, Dever GE, Choi ST (2002) Low birth weight is associated with elevated serum lipoprotein(a) in white and black American children ages 5-11 y. Public Health 116:33-38 (Pubitemid 34223924)
25. Kwiterovich PO Jr, Virgil DG, Garrett ES, Otvos J, Driggers R, Blakemore K, Cockrill SL, Macfarlane RD (2004) Lipoprotein heterogeneity at birth: influence of gestational age and race on lipoprotein subclasses and Lp(a) lipoprotein. Ethn Dis 14:351-359 (Pubitemid 39140076)
26. Aasvee K, Jauhiainen M, Kurvinen E, Jordania R, Sundvall J, Ehnholm C (1999) Lipoprotein(a), apolipoprotein A-I and B serum levels in young families from Tallinn, Estonia. Relationships with other cardiovascular risk factors and nationality. Scand J Clin Lab Invest 59:179-189
27. Preis SR, Pencina MJ, Hwang SJ, D'Agostino RB, Savage PJ, Levy D, Fox CS (2009) Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham heart study. Circulation 120:212-220
28. Koschinsky ML, Marcovina SM (2003) The relationship between lipoprotein(a) and the complications of diabetes mellitus. Acta Diabetol 40:65-76 (Pubitemid 36850921)
29. Labudovic DD, Toseska KN, Alabakovska SB, B Todorova B (2003) Apoprotein(a) phenotypes and plasma lipoprotein(a) concentration in patients with diabetes mellitus. Clin Biochem 36:545-551 (Pubitemid 37244017)
30. Alagozlu H, Gultekin F, Candan F (2000) Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients? Nutr Metab Cardiovasc Dis 10:204-208
31. Chang CJ, Kao JT, Wu TJ, Lu FH, Tai TY (1995) Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control. Diabetes Care 18:1191-1194
32. Csaszar A, Dieplinger H, Sandholzer C, Karadi I, Juhasz E, Drexel H, Halmos T, Romics L, Patsch JR, Utermann G (1993) Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia 36:47-51 (Pubitemid 23018334)
33. Klausen IC, Schmidt EB, Lervang HH, Gerdes LU, Ditzel J, Faergeman O (1992) Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest 22:538-541
34. Rainwater DL, MacCluer JW, Stern MP, VandeBerg JL, Haffner SM (1994) Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes 43:942-946
35. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302:412-423
36. Zlatohlavek L, Zidkova K, Vrablik M, Haas T, Prusikova M, Svobodova H, Ceska R (2008) Lipoprotein(a) and its position among other risk factors of atherosclerosis. Physiol Res 57:777-783
37. Agoston-Coldea L, Rusu LD, Zdrenghea D, Rusu ML, Pop D, Craciun A, Poanta L, Gatfosse M, Rosenstingl S, Mocan T (2008) Lipoprotein(a) and lipid and non-lipid risk factors in coronaries risk assessment. Rom J Intern Med 46:137-144
38. Tselmin S, Julius U, Muller G, Fischer S, Bornstein SR (2009) Cardiovascular events in patients with increased lipoprotein(a) - retrospective data analysis in an outpatient department of lipid disorders. Atheroscler Suppl 10:79-84
39. Sawabe M, Tanaka N, Nakahara K, Hamamatsu A, Chida K, Arai T, Harada K, Inamatsu T, Ozawa T, Naka MM, Matsushita S (2009) High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart 95:1997-2002
40. Katulanda GW, Katulanda P, Adler AI, Peiris SR, Draisey I, Wijeratne S, Sheriff R, Matthews DR, Shine B (2010) Apolipoproteins in diabetes dyslipidaemia in South Asians with young adult-onset diabetes: distribution, associations and patterns. Ann Clin Biochem 47:29-34
41. Eshtiaghi R, Esteghamati A, Nakhjavani M Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 65:262-266
42. Matthan NR, Jalbert SM, Barrett PH, Dolnikowski GG, Schaefer EJ, Lichtenstein AH (2008) Gender-specific differences in the kinetics of nonfasting TRL, IDL, and LDL apolipoprotein B-100 in men and premenopausal women. Arterioscler Thromb Vasc Biol 28:1838-1843
43. Nakagami F, Nakagami H, Osako MK, Iwabayashi M, Taniyama Y, Doi T, Shimizu H, Shimamura M, Rakugi H, Morishita R (2010) Estrogen attenuates vascular remodeling in Lp(a) transgenic mice. Atherosclerosis 211(1):41-47
44. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB (2000) Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283:1845-1852 (Pubitemid 30207621)
45. Hemelaar M, van der Mooren MJ, Mijatovic V, Bouman AA, Schijf CP, Kroeks MV, Franke HR, Kenemans P (2003) Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study. Menopause 10:550-558 (Pubitemid 40228151)
46. Suk Danik J, Rifai N, Buring JE, Ridker PM (2008) Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 52:124-131 (Pubitemid 351885446)
47. Rosenson RS, Tangney CC, Mosca LJ (1998) Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women. Arterioscler Thromb Vasc Biol 18:1902-1905 (Pubitemid 28565752)
48. White RE, Gerrity R, Barman SA, Han G (2010) Estrogen and oxidative stress: a novel mechanism that may increase the risk for cardiovascular disease in women. Steroids 75(11):788-793